It is well known that the CYP2C19 genetic polymorphism influences the pharmacokinetics
and pharmacodynamics of proton pump inhibitors (PPIs), but no report has addressed the …

Objective Omeprazole, lansoprazole and rabeprazole have been widely used as proton
pump inhibitors (PPIs). They can be metabolized in the liver by CYP2C19, a polymorphic …

Purpose. To predict the CYP2C19 genotype-dependence in anti-Helicobacter pylori (H.
pylori) therapy when lansoprazole or rabeprazole was used instead of omeprazole as a …

BACKGROUND: PPIs are widely used in peptic diseases, and this paper is to investigate the
kinetic characteristics of a new PPI ilaprazole in Chinese healthy subjects and the …

Introduction The aim of therapeutic regimens using proton pump inhibitors (PPIs) in patients
with acid-related diseases is to potently inhibit acid secretion for the full 24 h. However …

Elucidating the sources of interindividual variability in drug response is one major issue in
clinical pharmacology, and it represents the basic requirement for the yet unfullfilled …

Proton pump inhibitors (PPIs) are used widely for the treatment of acid-related disorders.
Despite their excellent efficacy and tolerance, the pharmacodynamics and pharmacokinetics …

Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole, rabeprazole,
esomeprazole, and pantoprazole, are mainly metabolized by CYP2C19 in the liver. There …

The aim of this study was to examine the effects of CYP2C19* 2 and* 3 genetic
polymorphisms on omeprazole pharmacokinetic (PK) and pharmacodynamic (PD) …

Proton pump inhibitors (eg omeprazole/esomeprazole, lansoprazole, pantoprazole,
rabeprazole) have a prominent role in the short-and long-term management of acid-related …